{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:52:18Z","timestamp":1793101938423,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Idiopathic inflammatory myopathies (IIM) are autoimmune disorders characterised by muscle inflammation, high creatine kinase (CK) levels and disability. Despite immunomodulating therapies, patients often experience progressive disease, resulting in refractory conditions or dependence on glucocorticoids (GC). This study addresses the efficacy and safety of immunoadsorption (IAS) in refractory IIM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, monocentric study was conducted on patients with highly active IIM subjected to IAS between January 2000 and September 2021. Inclusion criteria were adult patients with confirmed IIM unresponsive to standard therapies, including GC and at least one disease-modifying antirheumatic drug. Primary end point was defined as minor improvement, requiring a\u2009\u2265\u200920% reduction in both daily GC dosage and CK levels at week 12, alongside patient comparative self-assessment (PCSA) rated as \u2018no change\u2019 or \u2018better\u2019. Secondary endpoints included moderate (\u226540%) and major (\u226560%) improvements at weeks 4, 8 and 12. Relapse rates were assessed over a 3-month period following the last IAS procedure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 23 refractory IIM patients treated with IAS. Primary end point was reached by 52.2% (n\u2009=\u200912) patients. Moderate improvement was observed in 8.7% (n\u2009=\u20092), 26.1% (n\u2009=\u20096) and 34.8% (n\u2009=\u20098) and major improvement in 8.7% (n\u2009=\u20092), 17.4% (n\u2009=\u20094) and 30.4% (n\u2009=\u20097) at weeks 4, 8 and 12, respectively. No unexpected adverse events were reported, with low relapse rates within 3\u2009months post-IAS (18%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IAS may be an effective adjunctive therapy in patients refractory to GC and conventional treatments, leading to rapid CK level reductions, decreased GC usage and improvements in PCSA and muscle function.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf289","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:48:28Z","timestamp":1748436508000},"page":"5304-5312","source":"Crossref","is-referenced-by-count":3,"title":["Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-3390","authenticated-orcid":false,"given":"Kastriot","family":"Kastrati","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Karonitsch","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanien","family":"Rajab","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Reindl-Schwaighofer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farsad","family":"Eskandary","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahra","family":"Pajenda","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mrak","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Maximilian","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Peter","family":"Kiener","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bonelli","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Derfler","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-1525","authenticated-orcid":false,"given":"Helga","family":"Radner","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2025100315131540300_keaf289-B1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025100315131540300_keaf289-B2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies\u2014a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"2025100315131540300_keaf289-B3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025100315131540300_keaf289-B4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025100315131540300_keaf289-B5","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"2025100315131540300_keaf289-B6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025100315131540300_keaf289-B7","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert Perspective: management of Refractory Inflammatory Myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025100315131540300_keaf289-B8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315131540300_keaf289-B9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025100315131540300_keaf289-B10","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025100315131540300_keaf289-B11","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/acr.23198","article-title":"Predictors of reduced health-related quality of life in adult patients with idiopathic inflammatory myopathies","volume":"69","author":"Feldon","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025100315131540300_keaf289-B12","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"key":"2025100315131540300_keaf289-B13","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/rheumatology\/keab629","article-title":"Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series","volume":"61","author":"Zhang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315131540300_keaf289-B14","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315131540300_keaf289-B15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jca.21968","article-title":"Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy","volume":"37","author":"Kruse","year":"2022","journal-title":"J Clin Apher"},{"key":"2025100315131540300_keaf289-B16","first-page":"S61","article-title":"Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy","volume":"64","author":"Schneider","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"2025100315131540300_keaf289-B17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00002480-199743010-00010","article-title":"Efficacy and safety of immunoglobulin apheresis","volume":"43","author":"Richter","year":"1997","journal-title":"Asaio J"},{"key":"2025100315131540300_keaf289-B18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1744-9987.13663","article-title":"Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications","volume":"26","author":"Fuchs","year":"2022","journal-title":"Ther Apher Dial"},{"key":"2025100315131540300_keaf289-B19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfr610","article-title":"Anti-A\/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption","volume":"27","author":"Wahrmann","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025100315131540300_keaf289-B20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2004.029660","article-title":"IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study","volume":"64","author":"Stummvoll","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025100315131540300_keaf289-B21","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215154","article-title":"Plasma Exchange in ANCA-Associated Vasculitis: a Narrative Review","volume":"10","author":"Tsiakas","year":"2021","journal-title":"J Clin Med"},{"key":"2025100315131540300_keaf289-B22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(83)91561-1","article-title":"Randomised trial of plasma exchange in mild systemic lupus erythematosus","volume":"1","author":"Wei","year":"1983","journal-title":"Lancet"},{"key":"2025100315131540300_keaf289-B23","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"326","author":"Lewis","year":"1992","journal-title":"N Engl J Med"},{"key":"2025100315131540300_keaf289-B24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315131540300_keaf289-B25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315131540300_keaf289-B26","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","article-title":"Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy","volume":"62","author":"Julien","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315131540300_keaf289-B27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025100315131540300_keaf289-B28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025100315131540300_keaf289-B29","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025100315131540300_keaf289-B30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3389\/fneur.2019.00554","article-title":"Biomarkers in inflammatory myopathies\u2014an expanded definition","volume":"10","author":"Benveniste","year":"2019","journal-title":"Front Neurol"},{"key":"2025100315131540300_keaf289-B31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2025100315131540300_keaf289-B32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025100315131540300_keaf289-B33","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol Sci"},{"key":"2025100315131540300_keaf289-B34","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/rheumatology\/keae096","article-title":"Where are we now in biological drugs for myositis?","volume":"63","author":"Neves","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315131540300_keaf289-B35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/rheumatology\/40.5.513","article-title":"Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?","volume":"40","author":"Schmaldienst","year":"2001","journal-title":"Rheumatology"},{"key":"2025100315131540300_keaf289-B36","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100315131540300_keaf289-B37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf289\/63393421\/keaf289.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5304\/63393421\/keaf289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5304\/63393421\/keaf289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:13:26Z","timestamp":1759518806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/10\/5304\/8152316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5,28]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf289","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,28]]}}}